FDA concerned about bone drug
- Share via
From Times Wire Services
Federal regulators say a drug from Pfizer Inc. and Ligand Pharmaceuticals Inc. effectively treats osteoporosis, but they are concerned about deaths, blood clots and other problems seen in company studies.
The Food and Drug Administration noted that women treated with Pfizer’s Fablyn were more likely to die of cancer or stroke than those taking a placebo. The FDA posted its review of the drug online in advance of a meeting Monday with outside advisors.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
